LALulia Al-Hillawi

Lulia Al-Hillawi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lulia Al-Hillawi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • P4 A multicentre experience of home faecal calprotectin (CalproSmartTM) testing during the COVID-19 pandemic

    by Lulia Al-Hillawi, Gavin Sewell, Lydia White, Cristina Garcia-Sueiro, Stefanos Kateroglou, Edel McDermott, Timothy Ambrose, Tim Raine, Alissa Walsh

    Introduction Faecal calprotectin (FCP) testing is useful in the assessment of patients with inflammatory bowel disease (IBD). Home FCP testing bypasses the laboratory providing an instant result for patient and clinician. Need for Home FCP testing was highlighted during the Covid-19 pandemic. Methods From May 2020 to March 2021, Oxford University Hospitals NHS Foundation Trust (OUHFT) and Cambridge University Hospitals NHS Foundation Trust (CUHFT) used the Home FCP test CalproSmartTM. Data from 798 FCP kits sent to patients from both Trusts was gathered using electronic patient records and the CalproSmartTM database including demographics, time to complete test, FCP result, and subsequent outcome. Qualitative data about patient experience of CalproSmartTM was collected via online platform SurveyMonkey® (OUHFT) and MyChart online patient portal (CUHFT). Results Patients were evenly matched between OUHFT and CUHFT: age (38 (17-81) vs 40 (17-79) years) and diagnosis: Crohn’s disease (54% vs 52%), UC (44% vs 40%), IBD-U (2% vs 4%), 2% unknown. OUHFT had a higher proportion of patients on biologics (52% vs 40%). CUHFT had more patients on immunomodulators (31% vs 18%) and steroids (11% vs 5%). Clinicians in an outpatient setting requested the most tests (71% CUHFT vs 58% OUHFT). IBD specialist nurses requested 34% at OUHFT vs 15% at CUHFT. In total, 48% of tests were completed (55% OUHFT vs 41% CUHFT). There was no difference in return rates across age-range, gender, diagnosis or medications. Average time to complete the test was 16 days at OUHFT vs 27 at CUHFT. FCP results meant that no investigation/change in therapy was required in 46% of patients who may have otherwise required endoscopy/imaging/additional medication (15% required an endoscopy and 4% imaging). Escalation of therapy occurred in 23% and de-escalation in 3%. Online surveys were returned by 99 patients who had been sent a Home FCP at OUHFT, and 148 at CUHFT. Overall, 74% of patients who completed it found the Home FCP easier than lab FCP and 85% stated they would prefer Home FCP testing in future. In those that tried but failed due to issues with the app/kit, 21% found the Home FCP easier/same as a lab test and 53% would try Home FCP again. Conclusions Home FCP tests were completed by approximately half of patients who were sent a CalproSmartTM kit with 85% of those responding to a survey stating that it was preferential to a laboratory test. More invasive investigations were often not required due to access to a Home FCP result. Home FCP has a promising role in IBD care.

  • P3 Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

    by Lulia Al-Hillawi, Sailish Honap, Samantha Baillie, Aaron Bancil, Klaartje Kok, Kamal Patel, Alissa Walsh, Peter Irving, Mark Samaan

    Introduction Ustekinumab is an IL-12/23 receptor antagonist licensed for the treatment of ulcerative colitis (UC). Clinical trial data were promising however real-world data are limited. The aim was to assess the safety and effectiveness of ustekinumab in UC in a real-world setting Methods This was a multicenter, retrospective, observational cohort study across four tertiary IBD referral units in the UK between February 2020 and January 2022. Disease activity was assessed using the Simple Clinical Colitis Activity Index (SCCAI). Clinical remission was defined as a SCCAI ≤2. The primary endpoints were rates of corticosteroid-free clinical remission (CSFR) at week 16 and at week 26. Objective disease assessment outcomes, including fecal calprotectin (FCAL), were also collected. Results 110 patients with UC [65% male; median age 40 (interquartile (IQR) range 29-59); 96% with prior biologic and/or tofacitinib exposure] with a median follow up duration of 28 weeks (IQR 17-47). CSFR was 36% (18/50) at week 16 and 33% (13/39) at week 26, corresponding with a significant fall in SCCAI from 6 (IQR 4-8) at baseline to 3 (IQR 0-5) at week 26, pConclusions In the largest real-world study to date, ustekinumab was shown to be effective with a reassuring safety profile in a refractory cohort of patients.

  • Open Access

    A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis

    by Victoria Tatiana Kronsten, Michael J. Colwill, Shadab Nayeemuddin, Jimmy K. Limdi, Christian Selinger, Glyn Scott, Lulia Al‐Hillawi, Shayon Salehi, Paul Blaker, Guy Chung‐Faye, et al.


  • Open Access

    P494 Can Patients Monitor Response To Ustekinumab In The Real World?

    by A J Walsh, L Matini, A Kormilitzin, J Wilson, S Lyden, L Al-Hillawi, R Kantschuster, L White, S Payton, O Brain, et al.

    Real time monitoring of patients with Crohn’s disease (CD) gives us the opportunity to examine disease trajectory. We have demonstrated the feasibility of using a monitoring platform with patient reported data, collected prospectively and routinely in clinical practice. The question is whether it can be used for specific drugs TrueColours-IBD (TC-IBD)is a real time, web based platform that through email prompts linked to questionnaires, collects longitudinal patient reported outcome measures (for CD, symptoms measured by Harvey Bradshaw Index (HBI) and quality of life by IBD Control-8). It is routinely used by >2000 patients in Oxford. This study examined 114 patients with Crohn’s: 45 males (median age 36, IQR 28–51) and 69 females (median age 34.8, IQR 28–47), treated with ustekinumab for a maximum of 16 months (range -2 months to 14 months). A linear mixed-effects model was used to approximate longitudinal trends of HBI and IBD Control-8. 3 individual items of the HBI scale (general well-being, abdominal pain & stool frequency) were also assessed. The TC-IBD platform has the capacity to analyse and show patients’ data automatically, using customised models and algorithms through the feedback loop (Fig 1). Model coefficients, intercept and slope were estimated using the restricted maximum likelihood (REML) approach. The intercept corresponds to the expected cohort mean value of the scale (e.g. HBI, IBD Control-8) at baseline (time zero) and the slope describes the rate of the change over time The models’ coefficients, the intercept and slope of both HBI and IBD Control-8 scales were statistically significant and are summarised in Table 1 with confidence intervals. Both linear trends (slopes) describing HBI (p<0.001) and IBD Control-8 (p<0.001) confirmed improvements for patients. The bowel movement component of the HBI dominated over general well-being and abdominal pain, while keeping a similar downward trend over time ( Fig 2 and Fig 3a,b) Statistical summary of linear models shown in Figs 2 and 3a,b Statistical summary of linear models shown in Figs 2 and 3a,b Patient reported data through the TC-IBD platform can be used for statistical analyses and continuous monitoring of drug effect over time. This analysis is limited by a lack of comparator group, but the models may be used with the TrueColours platform as a decision support tool for other drugs